BLAINJECTIONINJECTABLE
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
TRULICITY (dulaglutide) by Eli Lilly and Company is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2014.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRULICITY (dulaglutide) is a GLP-1 receptor agonist administered via weekly subcutaneous injection for the treatment of type 2 diabetes mellitus. It works by mimicking glucagon-like peptide-1, a hormone that regulates blood glucose levels and promotes insulin secretion. The drug also carries cardiovascular benefits, reducing the risk of major adverse cardiac events in patients with established cardiovascular disease.
$7.4BPart D
PeakTRULICITY remains a peak-revenue product with sustained high-volume claims, indicating stable commercial teams and ongoing investment in market defense against emerging competitors.
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
GLP-1 Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Started Sep 2026
170 enrolled
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
Started Dec 2025
20 enrolled
Type 2 Diabetes Mellitus (T2DM)
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Started Jan 2025
55 enrolled
Type 2 Diabetes
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
Started Jul 2024
600 enrolled
Type2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Started Jan 2023
623 enrolled
T2DMType 2 Diabetes Mellitus
Worked on TRULICITY at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.